Rational therapy for relapsing multiple sclerosis
作者： Jerry S Wolinsky
DOI: 10.1016/S1474-4422(03)00375-2
关键词:
摘要: The surface expression of 41 integrin (VLA-4) and LFA-1 is increased after T-cell activation. Expression VCAM-1—the major ligand for integrin—is on luminal endothelial-cell surfaces in active CNS plaques, as the ICAM-1, main LFA-1. ability or to bind VCAM-1 respectively, initiate migration activated T cells monocytes into can be inhibited by various methods: drugs that reduce (eg, statins); 8 monoclonal antibodies directly block interaction with availability ICAM-1 surface; antagonist peptides simulate binding regions VCAM-1. 9
elsevier.com
sci-hub.se 参考文章(10)
O. Neuhaus, S. Strasser-Fuchs, F. Fazekas, B.C. Kieseier, G. Niederwieser, H.P. Hartung, J.J. Archelos, Statins as immunomodulators Comparison with interferon-β1b in MS Neurology. ,vol. 59, pp. 990- 997 ,(2002) , 10.1212/WNL.59.7.990
G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, B Brochet, I Berry, Y Rolland, J C Froment, E Cabanis, M T Iba-Zizen, J M Gandon, H M Lai, I Moseley, O Sabouraud, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 62, pp. 112- 118 ,(1997) , 10.1136/JNNP.62.2.112
Luc J.W. van der Laan, Annette van der Goes, Marca H.M. Wauben, Sigrid R. Ruuls, Ed A. Döpp, Corline J.A. De Groot, Taco W. Kuijpers, Mariano J. Elices, Christine D. Dijkstra, Beneficial effect of modified peptide inhibitor of alpha4 integrins on experimental allergic encephalomyelitis in Lewis rats. Journal of Neuroscience Research. ,vol. 67, pp. 191- 199 ,(2002) , 10.1002/JNR.10095
Jerry S. Wolinsky, Ponnada A. Narayana, Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain Current Opinion in Neurology. ,vol. 15, pp. 247- 251 ,(2002) , 10.1097/00019052-200206000-00004
Gianvito Martino, Luciano Adorini, Peter Rieckmann, Jan Hillert, Boris Kallmann, Giancarlo Comi, Massimo Filippi, Inflammation in multiple sclerosis: the good, the bad, and the complex Lancet Neurology. ,vol. 1, pp. 499- 509 ,(2002) , 10.1016/S1474-4422(02)00223-5
DH Miller, OA Khan, WA Sheremata, LD Blumhardt, GP Rice, MA Libonati, AJ Willmer-Hulme, CM Dalton, KA Miszkiel, PW O’Connor, International Natalizumab Multiple Sclerosis Trial Group, None, A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis The New England Journal of Medicine. ,vol. 348, pp. 15- 23 ,(2003) , 10.1056/NEJMOA020696
V. W. Yong, Differential mechanisms of action of interferon-β and glatiramer acetate in MS Neurology. ,vol. 59, pp. 802- 808 ,(2002) , 10.1212/WNL.59.6.802
Hans-Peter Hartung, Richard Gonsette, Nikolaus Konig, Hubert Kwiecinski, Andreas Guseo, Sean P Morrissey, Hilmar Krapf, Thomas Zwingers, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet. ,vol. 360, pp. 2018- 2025 ,(2002) , 10.1016/S0140-6736(02)12023-X
Graziella Filippini, Luca Munari, Barbara Incorvaia, George C Ebers, Chris Polman, Roberto D'Amico, George PA Rice, Interferons in relapsing remitting multiple sclerosis: a systematic review. The Lancet. ,vol. 361, pp. 545- 552 ,(2003) , 10.1016/S0140-6736(03)12512-3
JS Wolinsky, Giancarlo Comi, Massimo Filippi, D Ladkani, S Kadosh, G Shifroni, European/Canadian Glatiramer Acetate Study Group, None, Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained Neurology. ,vol. 59, pp. 1284- 1286 ,(2002) , 10.1212/WNL.59.8.1284